GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 20 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for Aeglea BioTherapeutics Stock and on which exchange is it traded?
The symbol for Aeglea BioTherapeutics is AGLE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Aeglea BioTherapeutics Stock?
Aeglea BioTherapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Aeglea BioTherapeutics Stock?
Aeglea BioTherapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Aeglea BioTherapeutics Stock.

What's the current price of Aeglea BioTherapeutics Stock?
As of the end of day on the 2024-02-26, the price of an Aeglea BioTherapeutics (AGLE) share was $12.01.

What is the 52-week high and low for Aeglea BioTherapeutics Stock?
The 52-week high for Aeglea BioTherapeutics Stock is $24.00 and the 52-week low is $2.65.

What is the market capitalization of Aeglea BioTherapeutics Stock?
As of the 2024-02-26, the market capitalization of Aeglea BioTherapeutics is 48.628M.

When is the next earnings date for Aeglea BioTherapeutics?
The upcoming earnings date for Aeglea BioTherapeutics is May 09, 2024.
Click to get the best stock tips daily for free!

About Aeglea BioTherapeutics

Aeglea BioTherapeutics Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, w... AGLE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT